MONOCLONAL ANTIBODY FOR CANCER TREATMENT (Q3133637): Difference between revisions

From EU Knowledge Graph
Jump to navigation Jump to search
(‎Changed an Item: Edited by the materialized bot - inferring region from the coordinates)
(‎Removed claims)
Property / budget
5,624,739.0 Euro
Amount5,624,739.0 Euro
UnitEuro
 
Property / budget: 5,624,739.0 Euro / rank
Normal rank
 
Property / co-financing rate
50.0 percent
Amount50.0 percent
Unitpercent
 
Property / co-financing rate: 50.0 percent / rank
Normal rank
 
Property / EU contribution
2,812,369.5 Euro
Amount2,812,369.5 Euro
UnitEuro
 
Property / EU contribution: 2,812,369.5 Euro / rank
Normal rank
 

Revision as of 15:06, 20 October 2021

Project Q3133637 in Spain
Language Label Description Also known as
English
MONOCLONAL ANTIBODY FOR CANCER TREATMENT
Project Q3133637 in Spain

    Statements

    0 references
    0 references
    16 February 2015
    0 references
    14 December 2015
    0 references
    ALTHIA HEALTH S.L.
    0 references
    0 references
    0 references

    40°25'0.12"N, 3°42'12.89"W
    0 references
    28079
    0 references
    VALIDACIÓN DE UN ANTICUERPO MONOCLONAL PARA LA DETECCIÓN Y TRATAMIENTO DE CÉLULAS MADRE DEL CÁNCER EN TUMORES DE CEREBRO (Spanish)
    0 references
    VALIDATION OF A MONOCLONAL ANTIBODY FOR THE DETECTION AND TREATMENT OF CANCER MOTHER CELLS IN BRAIN TUMORS (English)
    0 references
    Madrid
    0 references

    Identifiers

    DGEPF/01/21/002-17/18
    0 references